Biogen Aktie
WKN: 789617 / ISIN: US09062X1037
14.01.2025 02:07:15
|
FDA Accepts Eisai And Biogen's BLA For Subcutaneous LEQEMBI For Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics License Application or BLA for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease. A Prescription Drug User Fee Act (PDUFA) action date is set for August 31, 2025.
If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector, the companies said.
LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, Great Britain, Mexico, and Macau. In November 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommending approval.
Eisai has submitted applications for approval of lecanemab in 17 countries and regions. The US FDA accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024 and set a PDUFA action date for January 25, 2025.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
21.07.25 |
NASDAQ-Handel: NASDAQ 100 zum Ende des Montagshandels in der Gewinnzone (finanzen.at) | |
21.07.25 |
Börse New York: NASDAQ 100 am Montagnachmittag freundlich (finanzen.at) | |
21.07.25 |
Freundlicher Handel in New York: So entwickelt sich der S&P 500 am Mittag (finanzen.at) | |
21.07.25 |
NASDAQ-Handel: NASDAQ Composite am Montagmittag mit Zuschlägen (finanzen.at) | |
21.07.25 |
Freundlicher Handel in New York: NASDAQ 100 am Mittag mit Zuschlägen (finanzen.at) | |
21.07.25 |
Gewinne in New York: NASDAQ 100 zum Start im Plus (finanzen.at) | |
21.07.25 |
NASDAQ Composite Index-Wert Biogen-Aktie: So viel Verlust hätte eine Investition in Biogen von vor einem Jahr bedeutet (finanzen.at) | |
18.07.25 |
Schwacher Handel in New York: NASDAQ 100 zum Ende des Freitagshandels im Minus (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
Biogen Inc | 110,85 | 2,31% |
|